Navigation Links
Linkwell Corporation Selected to Train and License all Disinfectant and Pest Control Professionals in China and for the Beijing Olympics
Date:4/11/2008

SHANGHAI, China, April 11 /Xinhua-PRNewswire-FirstCall/ -- Linkwell Corporation (Linkwell) (OTC Bulletin Board: LWLL), a leading developer, manufacturer and distributor of healthcare related disinfectants in China, announced today that its wholly owned subsidiary Shanghai LiKang Disinfection Hi-Tech Company, Ltd., (LiKang Disinfectant) was selected by the Chinese Ministry of Health (MOH) and Ministry of Human Resources and Social Security (MOHRSS) to implement China's new disinfection vocational training and licensing program. The MOH and MOL created the program to improve China's public health safety security by standardizing the disinfectant industry's qualification and licensing standards.

Recently, the Vocational Ability Authentication Centers, a division of MOH sponsored an initiatives seminar of leading industry experts, to develop and implement a national training and licensing program for the disinfectant industry. Leading this effort were Mr. Liubo Zhang, the Chairman of the Office of Infection Control (a division of the Chinese Center for Disease Control and Prevention); Mr. Hualin Yang, the Secretary-General of the China Pest Infestation Control and Sanitation Association (a division of China's Ministry of Agriculture); Mr. Xuelian Bian, the Vice Director of the Shanghai Disinfection Association, and Chairman & CEO of Linkwell; and experts from the esteemed Beijing Xiehe and Shanghai Ruijin Hospitals.

These industry experts adapted LiKang Disinfectant's education program and recommended that it become China's official program. The Chairmen of MOH and MOHRSS accepted the experts' recommendation for standardized national vocational training and licensing program, and signed exclusive agreements with LiKang Disinfectant to implement and manage the program. In coordination with the China Pest Infestation Control and Sanitation Association, LiKang Disinfectant will initiate the first training class for the disinfection and pest control professionals supporting the 2008 Beijing Olympics.

"This national training and licensing program will provide essential health services for the Beijing Olympics and all of China," commented Xuelian Bian, "being selected to implement and manage this monumental program is an honor for LiKang Disinfectant and provides several new business opportunities." In addition to direct compensation for the training, LiKang Disinfectant's management believes the increase in prestige, and brand recognition will help sales of their disinfectant products.

Linkwell estimates there are one million disinfectant and pest control professionals who need this training and licensing. Management also believes they are well positioned to benefit from this program as these professionals commence the mandatory training and licensing, which will be conducted exclusively by LiKang Disinfectant's experts, using LiKang Disinfectant's products.

About Linkwell Corporation

Linkwell develops, manufactures and distributes disinfectant healthcare products in China through its subsidiary LiKang Disinfectant. Linkwell's disinfectant healthcare products are a nationally recognized domestic Chinese brand in this market segment. Linkwell products include disinfectants in liquid, tablet, powder and aerosol form. Through LiKang Disinfectant, Linkwell has a national marketing and sales presence throughout all 22 provinces, 5 autonomous regions, and 4 special municipalities of China. For more information, please visit http://www.lwll.us/ .

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations or beliefs, including, but not limited to, statements concerning Linkwell's operations, financial performance and condition. For this purpose, statements that are not statements of historical fact may be deemed to be forward-looking statements. Linkwell cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, but not limited to, the impact of competitive products, pricing and new technology; changes in consumer preferences and tastes; effectiveness of marketing; changes in laws and regulations; fluctuations in costs of production; and other factors as those discussed in Linkwell's reports filed with the Securities and Exchange Commission from time to time. In addition, Linkwell disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

Investor Relations

Craig Bird

Segue Ventures LLC

Tel: +1-215-885-4981

Email: chbird@segue.biz


'/>"/>
SOURCE Linkwell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Linkwell Chairman & CEO Addresses the Association of Chinese Nosocomial Infections Professional Committee
2. Linkwell Corporations Skin Disinfectant Product Chosen for 2008 Beijing Olympic Games
3. Shanghai Disinfection Association and Linkwell Corporation Co-Establish the Shanghai Disinfection Association Laboratory Center
4. Linkwell Corp to File to Extend Filing Date for 2007 Form 10-K
5. Linkwell Corporation Year-End 2007 Earnings Release and Conference Call Notice
6. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
7. Brooke Franchise Corporation Announces Selected July Results
8. MedThink Communications Retained by NanoBio Corporation
9. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
10. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
11. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 2016 , ... "FCPX Overlay Glare is a tool that utilizes light found ... or complicated compositing," said Christina Austin - CEO of Pixel Film Studios. , ... lights that simulates the look of a glare. Just drag and drop to ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... been featured in SuperbCrew magazine, a leading online tech news platform connecting technology ... now featured on SuperbCrew.com, explores the state of enterprise mobility security today, and ...
(Date:12/5/2016)... ... , ... “Epilepsy Awareness,” which can be found at the ... about epilepsy, bearing down on the social stigma and lack of public education ... within their lifetime. With such a large percentage of people affected, it’s critically ...
(Date:12/5/2016)... ... December 05, 2016 , ... Eating disorders are equal ... Castlewood Treatment Centers has always been to promote the power of recovery, and ... possible. In that spirit, Castlewood has announced two new hires, both Outreach Directors ...
(Date:12/5/2016)... Shrewsbury, PA (PRWEB) , ... December 05, 2016 , ... ... of necessity for the betterment of both the smaller rider and the horse. Smaller ... performance. The Saddle Sidekick is designed to fit over a properly fitted western saddle ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)... -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ), the ... and manufacturing data that support SB-525, its gene therapy program ... of the American Society of Hematology (ASH) being held in ... 2016. "We have developed an improved gene therapy ... highly competitive, and we remain on track to file an ...
(Date:12/5/2016)... Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., a ... data from two Phase I trials evaluating its ... 58th annual meeting of the American Society of ... . The two datasets show encouraging efficacy ... leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), ...
Breaking Medicine Technology: